<DOC>
	<DOCNO>NCT00623402</DOCNO>
	<brief_summary>To evaluate efficacy safety combine treatment Sorafenib ( Nexavar® ) pegylated interferon-α-2b ( PegIntron® ) patient malignant melanoma stage IV .</brief_summary>
	<brief_title>Combined Treatment Sorafenib Pegylated Interferon α2b Stage IV Metastatic Melanoma</brief_title>
	<detailed_description>This prospective non-randomized , multicenter Phase II Study evaluate efficacy safety combine treatment Sorafenib ( Nexavar® ) pegylated interferon-α-2b ( PegIntron® ) patient malignant melanoma stage IV . The investigator determine disease control rate ( CR , PR , SD ) 8 week treatment pegylated interferon- α-2b ( 3 µg/kg body weight s.c. week ) combine Sorafenib 2x 400 mg ( 2 tablet orally , twice daily )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically document metastatic melanoma classify stage IV ( AJCC 2002 ) cutaneous origin . ≥ 18 year age ECOG performance status 0 1 Patients received systemic treatment stage IV disease ( study = `` firstline '' treatment ) . Patients progressive disease ( PD ) stage IV prior treatment interferon well patient already treat Sorafenib include . The following allowed : adjuvant interferon treatment ( without progressive disease treatment ! ) vaccine therapy resect stage IIII disease palliative surgery radiotherapy stage IV disease prior cytokine chemotherapy treatment localregional disease isolate limb perfusion intralesional therapy Life expectancy &gt; 6 month . Patients must measurable disease define &gt; = 1 pretreated unidimensional measurable lesion &gt; = 20 mm ( conventional technique ) &gt; = 10 mm spiral CT/MRI . Patients must adequate hematological , renal liver function define laboratory value perform within 14 day prior study inclusion : absolute neutrophil count ( ANC ) &gt; 1.5 x 109/l platelet count &gt; 100 x 109/l hemoglobin &gt; 10 g/dl ( &gt; 6.2 mmol/l ) serum creatinine &lt; = 1.5 x upper limit institutional value total serum bilirubin &lt; = 1.5x upper limit institutional value ALAT ASAT &lt; = 2.5x upper limit institutional value ( exception : liver metastasis ) In addition : Patients suffer frequent vomit medical condition could interfere oral medication intake . Negative pregnancy test woman childbearing potential perform within 7 day prior start treatment . Women childbearing potential must agree use effective method contraception ( PearlIndex &lt; 1 , e.g . hormonal contraception include combined oral contraceptive pill , transdermal patch , contraceptive vaginal ring , intrauterine device sterilization ) treatment least 6 month thereafter . Men must agree use effective method contraception treatment least 6 month thereafter . Patients understand inform consent need sign consent Ocular mucosal melanoma . History evidence brain metastasis . Patients LDH value higher 2x upper limit institutional value . Patients thyroid dysfunction responsive therapy . Patients uncontrolled diabetes mellitus . Patients prior active autoimmune disease autoimmune hepatitis . Cardiac disease : congestive heart failure &gt; class II NYHA , patient must unstable angina new onset angina myocardial infarction within past 6 month . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal management . Active clinically serious infection &gt; CTCAE Grade 2 . Patients HIV positive AIDS . Thrombotic embolic event include transient ischemic attack within past 6 month . Evidence history bleed diathesis coagulopathy . Therapeutic anticoagulation Vitamin K antagonists warfarin , heparins heparinoids . Low dose warfarin permit INR &lt; 1.5 . Low dose aspirin permit . Known suspected allergy Sorafenib ingredient Sorafenib PEGIFNα 2b ingredient PEGIFNα 2b interferone . Previous cancer distinct primary site histology melanoma except cervical cancer situ , treat basal cell carcinoma , superficial bladder tumor cancer curatively treat 3 year prior study entry . Substance abuse , medical psychological condition may interfere patient´s participation study . Patients medication require chronic systemic corticosteroid . Patients prior systemic anticancer treatment last 2 week . Patients severe liver disease severe renal disease . Patients seizure disorder require anticonvulsant therapy . Patients severe debilitate disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Metastatic melanoma</keyword>
	<keyword>Pegylated interferon</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>PegIntron</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>melanoma ( skin )</keyword>
</DOC>